NanoPass Technologies Ltd. is a pioneer in the development and commercialization of nearly painless intradermal delivery solutions for vaccines and drugs. Its flagship product, the 0.6mm MicronJet600 microneedle, is the first and only true (<1mm) microneedle to receive FDA clearance as an intradermal delivery device for substances approved for delivery below the surface of the skin and is also CE certified. It has proven its efficacy in vaccination delivery with improved potency, immunogenicity and dose sparing1-8,10. Supported by extensive clinical data and regulatory approvals in leading markets, NanoPass is ready to expand its reach by partnering with pharma companies aiming to provide better patient care worldwide. The company supports multiple phase I-III clinical studies and is actively pursuing additional partnerships with vaccine developers worldwide. Nanopass is ISO13485 certified.